{"data":[{"accessionNo":"0001851416-26-000030","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-09-03","reportingPerson":"Streeterville Capital LLC","reportingCik":null,"personType":"OO","sharesOwned":122963,"percentOfClass":0.6,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001851416-26-000030","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-09-03","reportingPerson":"Streeterville Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":122963,"percentOfClass":0.6,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001851416-26-000030","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-09-03","reportingPerson":"John M Fife","reportingCik":null,"personType":"IN","sharesOwned":122963,"percentOfClass":0.6,"filedAt":"2026-09-03","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001172661-26-003625","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Armistice Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":729755,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001172661-26-003625","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Steven Boyd","reportingCik":null,"personType":"HC,IN","sharesOwned":729755,"percentOfClass":4.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001851416-26-000026","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-08-11","reportingPerson":"Streeterville Capital LLC","reportingCik":null,"personType":"OO","sharesOwned":1812031,"percentOfClass":9.3,"filedAt":"2026-08-11","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001851416-26-000026","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-08-11","reportingPerson":"Streeterville Management, LLC","reportingCik":null,"personType":"OO","sharesOwned":1812031,"percentOfClass":9.3,"filedAt":"2026-08-11","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001851416-26-000026","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-08-11","reportingPerson":"John M Fife","reportingCik":null,"personType":"IN","sharesOwned":1812031,"percentOfClass":9.3,"filedAt":"2026-08-11","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-083931","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Michael C. Skaff","reportingCik":"0002074003","personType":"IN","sharesOwned":2783102,"percentOfClass":19.9,"filedAt":"2026-07-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-083931","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"SP Manager LLC","reportingCik":null,"personType":"OO","sharesOwned":2783102,"percentOfClass":19.9,"filedAt":"2026-07-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-083931","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"V-Co Investors 3 LLC","reportingCik":"0002114460","personType":"OO","sharesOwned":1353625,"percentOfClass":9.7,"filedAt":"2026-07-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-083931","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"V-Co Investors 2 LLC","reportingCik":"0002114466","personType":"OO","sharesOwned":828000,"percentOfClass":5.9,"filedAt":"2026-07-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-083931","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"V-CO Investors LLC","reportingCik":"0002049575","personType":"OO","sharesOwned":514498,"percentOfClass":3.7,"filedAt":"2026-07-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-083931","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"V-Co Investors 4 LLC","reportingCik":"0002137034","personType":"OO","sharesOwned":86979,"percentOfClass":0.6,"filedAt":"2026-07-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001172661-26-002126","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Armistice Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1115859,"percentOfClass":8.27,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001172661-26-002126","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven Boyd","reportingCik":null,"personType":"HC,IN","sharesOwned":1115859,"percentOfClass":8.27,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-039298","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Michael C. Skaff","reportingCik":"0002074003","personType":"IN","sharesOwned":2696123,"percentOfClass":19.9,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-039298","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"SP Manager LLC","reportingCik":null,"personType":"OO","sharesOwned":2696123,"percentOfClass":19.9,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-039298","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"V-Co Investors 3 LLC","reportingCik":"0002114460","personType":"OO","sharesOwned":1353625,"percentOfClass":10,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-039298","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"V-Co Investors 2 LLC","reportingCik":"0002114466","personType":"OO","sharesOwned":828000,"percentOfClass":6.1,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"},{"accessionNo":"0001104659-26-039298","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001716166","issuerName":"Vivos Therapeutics, Inc.","ticker":"VVOS","cusip":"92859E207","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"V-CO Investors LLC","reportingCik":"0002049575","personType":"OO","sharesOwned":514498,"percentOfClass":3.8,"filedAt":"2026-04-02","canonicalUrl":"https://xoomar.com/markets/stocks/vvos"}],"updatedAt":"2026-10-25T00:03:31.203Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/vvos","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}